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Summary
 
The development of a normal T cell repertoire in the thymus is dependent on the interplay be-
tween signals mediating cell survival (positive selection) and cell death (negative selection or death
by neglect). Although the CD28 costimulatory molecule has been implicated in this process, it
has  been difficult to establish a role for the other major costimulatory molecule, cytotoxic T
lymphocyte antigen (CTLA)-4. Here we report that in vivo stimulation through the T cell receptor
(TCR)–CD3 complex induces expression of CTLA-4 in thymocytes and leads to the association of
CTLA-4 with the SH2 domain–containing phosphatase (SHP)-2 tyrosine phosphatase. Moreover,
intrathymic CTLA-4 blockade dramatically inhibits anti-CD3–mediated depletion of CD4
 
1
 
CD8
 
1
 
double positive immature thymocytes. Similarly, anti-CD3–mediated depletion of CD4
 
1
 
CD8
 
1
 
double positive cells in fetal thymic organ cultures could also be inhibited by anti–CTLA-4 anti-
bodies. Thus, our data provide evidence for a role of CTLA-4 in thymic selection and suggest a
novel mechanism contributing to the regulation of TCR-mediated selection of T cell repertoires.
Key words: cytotoxic T lymphocyte antigen 4 (CD152) • CD28 • costimulation • T cell 
development • tyrosine phosphatase SHP-2
 
D
 
uring thymocyte differentiation, progenitor T cells
proceed through a process of positive and negative
selection upon ligation of the TCR (1). The outcome of
TCR ligation is believed to be dependent on the avidity of
the interaction between the TCR and the MHC (2, 3), and
on the differentiation status of the T cell progenitor (4). This
process has also been suggested to include a role for T cell
costimulatory molecules, notably the CD28 receptor.
The CD28/CTLA-4/B7 cell surface molecules are es-
sential for the control of T cell responses regulating a com-
plex pathway of costimulatory signals (5, 6). Although sig-
naling through CD28 leads to the enhancement and
maintenance of T cell activation and proliferation, accumu-
lating data suggest that CTLA-4 functions as a negative
regulator of T cell activity (7–10). CTLA-4 and CD28 also
differ in their expression pattern and in avidity to their
common ligands, B7-1 (CD80) and B7-2 (CD86). CD28,
which binds the B7 molecules with a relatively low avidity,
is constitutively expressed on the cell surface of resting and
activated T cells (11). On the other hand, CTLA-4 is tran-
siently expressed at the cell surface only after T cell activa-
tion. The avidity for interaction with the B7 molecules is
 
z
 
10–100-fold higher than for CD28 (12–14). Recent
studies have demonstrated that after T cell activation the
majority of CTLA-4 is localized in cytoplasmic vesicles
rather than on the cell surface, and that once expressed on
the membrane it is rapidly internalized (15, 16). These data
suggest that CTLA-4 intracellular trafficking is tightly
regulated, and could explain the low levels of expression
detected at the cell surface.
The observation that the ligands for the CD28/CTLA-4
receptors, the B7 molecules, could be expressed in the thymic
epithelium (17, 18) suggested a functional role of these
costimulatory receptors during thymocyte differentiation. In
line with this, the CD28 receptor has been reported to be in-
volved in the rescue of CD4
 
1
 
CD8
 
1
 
 double positive (DP)
 
1
 
thymocytes from death by neglect, and to be required for in-
duction of apoptosis during negative selection (19–21). Dur-
ing T cell differentiation, CD28 is expressed on 90–95% of
thymocytes and can be detected already at the CD4
 
2
 
CD8
 
2
 
double negative (DN) pre-T cell stage. The expression level
is upregulated in DP thymocytes and decreases again in
mature CD4 and CD8 single positive (SP) T cells (11).
 
1
 
Abbreviations used in this paper:
 
 DN, double negative; DP, double positive;
FTOC, fetal thymic organ culture; RT, reverse transcriptase; SHP, SH2
domain–containing phosphatase; SP, single positive.
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A Role for CTLA-4 in the Thymus
 
Although CTLA-4 has been suggested to play a major
role in the establishment of peripheral self-tolerance as well
as in the regulation of normal T cell immunity (6, 22, 23),
its potential role during thymocyte development is more
controversial (24–28). Evidence for basal expression of
CTLA-4 in non activated thymocytes comes from the orig-
inal report by Brunet et al. where a weak but still detect-
able RNA expression was seen by Northern blot analysis
(29). Low expression of CTLA-4 protein on the surface of
fresh thymocytes has also been reported (26).
We have addressed the role of CTLA-4 in T cell devel-
opment by analyzing CTLA-4 expression and function in
thymocytes activated in vivo through CD3 stimulation.
We report that CTLA-4 is induced and associates with the
SHP-2 tyrosine phosphatase upon in vivo
 
 
 
anti-CD3 ad-
ministration. Intrathymic CTLA-4 blockade dramatically
inhibits anti-CD3–mediated depletion of DP immature
thymocytes. Furthermore, CTLA-4 blockade was also
found to inhibit anti-CD3–mediated depletion of DP thy-
mocytes in fetal thymic organ cultures (FTOCs), demon-
strating that the observed effect is not due to an indirect ef-
fect executed upon peripheral T cells. Together, these
results provide evidence for a role of CTLA-4 in thymic se-
lection and suggest a novel mechanism contributing to the
regulation of TCR-mediated selection of T cell repertoires.
 
Materials and Methods
 
Mice.
 
C57BL/6 (B6) mice were purchased from Bomholt-
gård Breeding & Research Centre (Ry, Denmark) and main-
tained in our own facility. All mice used in the experiments were
6–10 wk old.
 
Antibodies.
 
Hamster anti-CD3 mAb (clone 145-2C11) was
purified in our laboratory from hybridoma culture supernatant by
affinity chromatography on Protein G column (Amersham Phar-
macia Biotech, Inc., Uppsala, Sweden). Supernatant from hybri-
doma producing hamster anti-FcR (clone 2.4G2) was used to
block FcRs during thymocyte staining. Anti-CTLA-4–PE (clone
UC10-4F10-11), control hamster IgG anti-TNP–PE (clone
G155-178), anti-CD4–FITC or –PE (clone H129.19), and anti-
CD8–biotin or –FITC (clone 53-6.7) were all purchased from
PharMingen (San Diego, CA).
 
In Vivo Anti-CD3 Treatment.
 
Groups of two to three mice
were injected with 100 
 
m
 
g (unless otherwise stated) of anti-CD3
intraperitoneally in 200 
 
m
 
l total volume, or with saline as control.
After different time points, thymi were explanted and single cell
suspension was prepared by passage through nylon mesh.
 
Intrathymic Injection.
 
Groups of three mice were intrathymi-
cally injected using a technique originally described by Scollay et al.
(30). In brief, mice were anesthetized, and after thymus exposure
between 5 and 8 
 
m
 
g of purified soluble anti–CTLA-4 mAb
(clone UC10-4F10-11, low endotoxin, sodium azide–free;
PharMingen) in a total volume of 10 
 
m
 
l was injected in each thy-
mus lobe. Control mice received either an equal amount of ham-
ster IgG anti-TNP (clone G155-178, low endotoxin, sodium
azide–free, PharMingen) or only saline. After mice recovered
from surgery, generally between 2 and 4 h, anti-CD3 was in-
jected intraperitoneally at the indicated doses. Mice were killed
24 h later and thymocytes were stained for flow cytometry analy-
sis as described below.
 
Staining and Flow Cytometry.
 
For CTLA-4 surface expression,
freshly isolated thymocytes were washed twice in staining buffer
(3% FCS and 0.01% sodium azide in PBS) before the stainings
were performed. In brief, 10
 
6
 
 cells were first incubated with 100 
 
m
 
l
of anti-FcR mAb supernatant for 30 min on ice to reduce unspe-
cific staining due to FcR binding of mAbs. After washing with
staining buffer, cells were triple stained with saturating concentra-
tions of anti-CD4–FITC, anti-CD8–biotin, and anti-CTLA-4–PE
for 30 min on ice followed by a final incubation with streptavidin
Cy-Chrome (PharMingen) for 30 min on ice to reveal biotiny-
lated mAb. For CTLA-4 intracellular staining, after FcR block-
ing, cells were first stained for surface markers, fixed in 2%
paraformaldehyde, washed twice in saponin buffer (0.03% sapo-
nin in PBS), and then permeabilized with 0.3% saponin in PBS
for 5 min on ice. Cells were then stained with anti-CTLA-4–PE
in the presence of 0.3% saponin for an additional 30 min, washed
extensively in saponin buffer, once in staining buffer, and finally
resuspended in PBS for FACS
 
Ò
 
 (Becton Dickinson, San Jose, CA)
analysis. Flow cytometry was performed with a FACScalibur
 
Ò
 
 cy-
tometer (Becton Dickinson), and CellQuest
 
Ò
 
 software (Becton
Dickinson) was used for data collection and analysis. At least 2 
 
3
 
10
 
4
 
 viable cells were acquired based on their morphology using
FCS/SSC parameters.
For detection of apoptosis by propidium iodide (PI) staining and
DNA content analysis, 10
 
6
 
 thymocytes recovered from FTOCs were
fixed in 70% ethanol for 2 h on ice, washed twice with PBS, and re-
suspended in hypotonic PI solution containing 0.1% sodium citrate,
0.1% Triton X-100, 50 
 
m
 
g/ml PI (Sigma Chemical Co., St. Louis,
MO), and 20 
 
m
 
g/ml RNAse (Sigma Chemical Co.). Cells were kept
at 4
 
8
 
C in the dark overnight before FACS
 
Ò
 
 analysis was performed.
Apoptotic cells were identified by hypodiploid DNA content.
 
FTOC.
 
Fetal thymi were isolated from B6 embryos at day
18.5 of gestational age under sterile conditions. Organ cultures
were set up as originally described (31) with slight modifications.
In brief, explants were divided into single lobes and put onto 25-
mm Nucleopore
 
Ò
 
 membranes (0.8 
 
m
 
m polycarbonate; Costar
Corp., Cambridge, MA) floating on 5 ml IMDM complete me-
dium (GIBCO BRL, Gaithersburg, MD), containing 1
 
3
 
 nones-
sential amino acids (GIBCO BRL), penicillin/streptomycin, 5 
 
3
 
10
 
2
 
5
 
 M 2-ME, 10% FCS, and 1 mM sodium pyruvate in six-well
culture plates (Costar Corp.), and incubated at 37
 
8
 
C with 5%
CO
 
2
 
. FTOCs were analyzed after 24 h of incubation in the pres-
ence or absence of the indicated soluble antibodies (10 
 
m
 
g/ml
anti-CD3, 10 
 
m
 
g/ml anti–CTLA-4).
 
RNA Extraction and Reverse Transcriptase PCR.
 
Total RNA was
isolated using the Ultraspec RNA isolation system (Biotecx Labs.,
Houston, Texas) according to the manufacturer’s indications. In
brief, thymi from anti-CD3 and saline-treated mice were explanted
and quickly frozen in liquid nitrogen. The thymi were then homo-
genized in lysis buffer and RNA was extracted with chloroform and
precipitated with isopropanol. For cDNA synthesis, 300 ng of total
RNA from each sample was incubated with oligo(dT) primer (Am-
ersham Pharmacia Biotech, Inc.) for 10 min at 70
 
8
 
C and chilled on
ice for 5 min. Samples were then incubated with 0.1 M dithiothrei-
tol, 500 
 
m
 
M dNTPs, 20 U RNase inhibitors (Boehringer Mann-
heim, Mannheim, Germany) for 2 min at room temperature before
1.5 
 
m
 
l (300 U) of SuperScript RNaseH-free reverse transcriptase
(RT; GIBCO BRL) was added. Samples were then incubated
for 2 min at room temperature followed by 1 h at 37
 
8
 
C and finally
5 min at 95
 
8
 
C. Amplification of synthetized cDNA from each sam-
ple was carried out with Dynazyme DNA polymerase (Finnzymer
OY, Espoo, Finland) in 50 
 
m
 
l reaction under the following condi-
tions: 95
 
8
 
C for 2 min, 55
 
8
 
C for 1 min, and 72
 
8
 
C for 1 min for a 
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total of 32 cycles. Specific primers were designed to amplify the
CTLA-4 coding region (sense primer: 5
 
9
 
-TCCTGTTGGGTTT-
TACTCTAC-3
 
9
 
; antisense primer: 5
 
9
 
-GAAATTGCCTCAG-
CTTTAG-3
 
9
 
) and hypoxanthine-guanine phosphoribosyl transferase
(HPRT) primers (sense: 5
 
9
 
-CACAGGACTAGAACACCTGC-3
 
9
 
;
antisense: 5
 
9
 
-GCTGGTGAAAAGGACCTCT-3
 
9
 
) were used as a
control for cDNA input and RT-PCR.
 
Immunoprecipitation of CTLA-4.
 
Sixty million fresh thymo-
cytes were resuspended in CHAPS lysis buffer (50 mM Tris, pH
7.2, 300 mM NaCl, 1 mM EDTA, 6 mM CHAPS, 2 mM
Pefabloc SC, 1 
 
m
 
g/ml leupeptin, 1 
 
m
 
g/ml aprotinin, and 1 mM
sodium vanadate). Lysis was allowed to proceed for 2 h at 4
 
8
 
C
and insoluble debris was removed by centrifugation at 25,000 
 
g
 
for 20 min at 4
 
8
 
C. Supernatants were diluted 1:2 with TNB
buffer (50 mM Tris, pH 7.2, 300 mM NaCl, and 2 mg/ml BSA)
and then precleared by mixing with 4 
 
m
 
l each of protein A–seph-
arose and Gammabind G–sepharose (Amersham Pharmacia Bio-
tech, Inc.) for 45 min at 4
 
8
 
C, followed by centrifugation at 500 
 
g
 
for 3 min at 4
 
8
 
C. Cleared supernatants were then incubated for
18 h at 4
 
8
 
C with 2 
 
m
 
g each of anti-CTLA-4 antibody. Immune
complexes were recovered by incubation with 4 
 
m
 
l each of pro-
tein A–sepharose and Gammabind G–sepharose for 45 min at
4
 
8
 
C, followed by centrifugation at 500 
 
g
 
 for 3 min at 4
 
8
 
C. Pellets
were washed twice in dilution buffer (10 mM Tris, pH 8.0, 140
mM NaCl, 0.1% Triton X-100, 0.1% bovine hemoglobin, and
0.025% sodium azide), once in TSA buffer (10 mM Tris, pH 8.0,
140 mM NaCl, and 0.025% sodium azide), and once in 50 mM
Tris, pH 6.8, and then the proteins were solubilized in 2
 
3
 
 SDS
loading buffer (100 mM Tris, pH 6.8, 4% SDS, 0.2% Bromophe-
nol blue, 200 mM dithiothreitol, and 20% glycerol). Samples
were boiled for 5 min before resolution by 8% SDS-PAGE.
 
Gel Electrophoresis and Western Blotting.
 
Polyacrylamide gels were
run using a Mini Protean II gel apparatus (Bio-Rad, Hercules,
CA) and then transferred to PVDF membrane (Pierce Chemical
Co., Rockford, IL) using a Sammy D Semi-dry blotter (Schlei-
cher and Schuell, Dassel, Germany). Blots were blocked over-
night in TBS-T (20 mM Tris, pH 7.5, 137.5 mM NaCl, and
0.1% Tween 20) containing 10% horse serum (TBS-T/HS). In-
cubations were in TBS-T/HS as follows: anti–SHP-2 (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA) 1:250, 2 h; biotiny-
lated donkey anti–rabbit (Amersham Pharmacia Biotech) 1:5,000,
2 h; and streptavidin-horseradish peroxidase (Pierce Chemical
Co.) 1:5,000, 1 h. Filters were washed overnight with several
changes of TBS-T, developed with Supersignal chemilumines-
cent substrate (Pierce Chemical Co.), and exposed to Cronex4
X-Ray film (Du Medical Scandinavia, Sollentua, Sweden).
 
Results
 
CTLA-4 Is Induced in Thymocytes after In Vivo CD3 Stim-
ulation.
 
To investigate whether CTLA-4 expression
could be induced on thymocytes by in vivo activation, we
analyzed the intracellular and membrane expression of
CTLA-4 on thymocytes before and after in vivo adminis-
tration of anti-CD3 mAbs. Mice were killed at different
time points after administration of anti-CD3 and thy-
mocytes were analyzed for intracellular and cell surface ex-
pression of CTLA-4 by flow cytometry (Fig. 1, 
 
A
 
 and 
 
B
 
).
Before in vivo activation by anti-CD3, no significant sur-
face expression of CTLA-4 was observed in any of the
main thymocyte subpopulations (Fig. 1 
 
B
 
). However, low
levels of CTLA-4 expression were observed intracytoplas-
matically in the DN and the CD4 SP thymocyte subpopu-
lations (Fig. 1 
 
A
 
). Upon in vivo activation, an upregulation
of CTLA-4 expression was observed in all thymocyte sub-
populations (Figs. 1 and 2). This upregulation of expression
occurred more rapidly in the intracytoplasmatic pool,
where it was already evident at 16 h after stimulation (Fig.
2). At the level of membrane expression, the increase in
CTLA-4 expression was slower, and significant upregula-
tion was observed in DP and SP thymocytes only 24 h after
stimulation (Figs. 1 
 
B
 
 and 2). In the DN subpopulation, the
upregulation of membrane expression was less pronounced
than in the other thymocyte subpopulations (Figs. 1 
 
B
 
 and 2).
Figure 1. CTLA-4 expression is induced upon in vivo anti-CD3
administration. Mice were injected intraperitoneally with 100 mg of anti-
CD3 mAbs or with saline as control. After 24 h mice were killed and thy-
mocytes were analyzed for CTLA-4 expression by three-color flow
cytometry. (A) Intracellular expression of CTLA-4: thymocytes were first
double stained with anti-CD4–FITC and anti-CD8–biotin surface mark-
ers, fixed, permeabilized, and finally incubated with anti–CTLA-4–PE.
(B) Cell surface expression of CTLA-4: thymocytes were triple stained
with anti-CD4–FITC, anti-CD8–biotin, and anti–CTLA-4–PE. In all
experiments biotin has been revealed by incubation with streptavidin Cy-
Chrome. Contour dot-plots represent CTLA-4 expression evaluated on
viable thymocyte subsets by differential gating based on CD4 and CD8
expression (boxes). These results are representative of at least three inde-
pendent experiments. 
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A Role for CTLA-4 in the Thymus
 
To confirm that the induced expression of CTLA-4 pro-
tein was accompanied by an increase in the transcription rate
of the 
 
Ctla-4
 
 gene, the levels of specific mRNA were esti-
mated using an RT-PCR approach. As illustrated in Fig. 3,
 
Ctla-4
 
–specific mRNA was increased in thymocytes upon in
vivo
 
 
 
anti-CD3 stimulation compared with thymocytes
recovered from mice injected with only saline (Fig. 3).
Together, these results demonstrated that the transcription
and protein expression of CTLA-4
 
 
 
can indeed be induced in
thymocytes upon in vivo stimulation with anti-CD3.
 
CTLA-4 Associates with SHP-2 Phosphatase after Anti-
CD3 Treatment.
 
Recently, immunoprecipitation studies
have shown that the SH2 domain–containing protein ty-
rosine phosphatase SHP-2 specifically associates with
CTLA-4 in peripheral T cells (32). These results have been
suggested to indicate a role for CTLA-4 in regulating TCR
signaling through recruitment of SHP-2 and interference
with the phosphorylation of TCR-associated kinases. To
determine whether a similar recruitment of SHP-2 could be
detected in in vivo activated thymocytes, we determined
the levels of SHP-2 associated with CTLA-4 in thymocytes
upon in vivo stimulation with anti-CD3. As illustrated in
Fig. 4, SHP-2 could be readily immunoprecipitated with
CTLA-4 from thymocytes after, but not before, in vivo
stimulation with anti-CD3 mAbs. Thus, in vivo stimulation
of thymocytes through the TCR–CD3 receptor complex
appears to result in an increase in the SHP-2 associated with
the CTLA-4 receptor. In contrast, no recruitment of the
homologous phosphatase SHP-1 was found in thymocytes
after anti-CD3 administration (data not shown).
 
Intrathymic CTLA-4 Blockade Prevents Anti-CD3–mediated
Depletion of Immature Thymocytes.
 
To examine the possi-
bility that the induced CTLA-4 expression would indeed
mediate a functional effect on thymocytes, we tested
whether blockade of the CTLA-4 receptor by intrathymic
injection of soluble anti-CTLA-4 mAbs could interfere
with the depletion of DP thymocyte mediated by anti-
CD3 treatment. Mice were first injected intrathymically
with soluble anti-CTLA-4, then treated with 100 
 
m
 
g of
anti-CD3 intraperitoneally. After 24 h, thymocytes were
analyzed for CD4 and CD8 expression (Fig. 5). Control
mice received saline intraperitoneally and/or saline or anti-
TNP hamster Ig intrathymically. In vivo administration of
anti-CD3 led to a rapid depletion of immature thymocytes
(Fig. 5, 
 
A
 
 and 
 
B
 
). As illustrated in Fig. 5 
 
D, intrathymic in-
jection of anti–CTLA-4 before anti-CD3 administration
significantly inhibited the anti-CD3–mediated depletion of
DP thymocytes, whereas control hamster Ig or saline had
no effect (Fig. 5, B and C). The observed effect was dose
dependent and primarily involved the compartment of DP
thymocytes (Fig. 5 E). Interestingly, the effect of CTLA-4
blockade was dramatic at doses of anti-CD3 up to 50 mg,
where the depletion of DP thymocytes was almost com-
pletely inhibited by intrathymic CTLA-4 blockade. How-
ever, the inhibitory effect of anti–CTLA-4 appears to be
overcome at increased doses of anti-CD3 (Fig. 5 E).
In Vitro CTLA-4 Blockade Prevents Anti-CD3–induced Ap-
optosis of DP Thymocytes in FTOCs. It could be argued
that the effect of in vivo anti-CD3 administration on thy-
Figure 2. Kinetics of CTLA-4 expression in the major thymocyte popula-
tions. Thymocytes were stained and analyzed by flow cytometry at different
time points after in vivo administration of anti-CD3 as described in Fig. 1 and
in Materials and Methods. DP, CD41CD81 double positives; SP, CD41 or
CD81 single positives; DN, CD42CD82 double negatives. One experiment
is shown of at least three independent experiments with similar results.
Figure 3. Expression of Ctla-4
mRNA in thymocytes upon in
vivo anti-CD3 treatment. RNA
was isolated from thymus after
24 h of treatment with 100 mg of
anti-CD3 or saline and analyzed
by RT-PCR for Ctla-4 RNA
expression. Hypoxanthine-gua-
nine phosphoribosyl transferase (HPRT) RNA expression is shown in the
lower panel as control for cDNA loading and RT-PCR. This experiment
is representative of two independent RT-PCRs.
Figure 4. CTLA-4 associates
with SHP-2 in in vivo activated
thymocytes.  Thymocytes from
mice treated for 24 h with 100
mg of anti-CD3 or with saline
only were lysed and CTLA-4
was immunoprecipitated with
anti–CTLA-4. Proteins were
subjected to SDS-PAGE, trans-
ferred to PVDF membrane, and
immunoblotted with anti–SHP-2
antibody as described in Materi-
als and Methods.1243 Cilio et al.
mocytes is an indirect effect mediated through the activa-
tion of peripheral T cells. Thus, it is not ruled out that the
inhibitory effect obtained by intrathymic injections of anti–
CTLA-4 could be the result of anti–CTLA-4 inhibition of
anti-CD3–activated peripheral T cells. To address this, we
investigated if the effect of CTLA-4 blockade could be di-
rectly observed on thymocytes in FTOCs. As illustrated in
Fig. 6, anti-CD3 stimulation of FTOCs increased the
number of apoptotic cells and decreased the number of DP
cells. This effect was inhibited by adding anti–CTLA-4 an-
tibodies to the culture, demonstrating a direct effect of
CTLA-4 blockade on thymocytes.
Discussion
We report here that expression of the costimulatory re-
ceptor CTLA-4 in thymocytes can be induced upon in
vivo stimulation through the TCR–CD3 receptor com-
plex. Cell surface expression of CTLA-4 was clearly ob-
served in DP as well as CD4 and CD8 SP thymocytes, but
cell surface expression had slower kinetics compared with
the induction of intracellular expression. Although surface
expression does not per se demonstrate functional rele-
vance, the inhibition of anti-CD3–mediated depletion of
DP thymocytes through the blockade of CTLA-4 provided
evidence for a functional role for CTLA-4 during thy-
mocyte differentiation. The observation that CTLA-4
blockade inhibits the anti-CD3–mediated depletion of thy-
mocytes in FTOCs further supports this notion. This obser-
vation also provides evidence for a direct functional effect of
CTLA-4 blockade on thymocytes, escaping the possibility
that the observed effect was mediated through inhibiting
peripheral T cells activated by the anti-CD3 treatment.
Accumulating data have suggested that CTLA-4 functions
as a negative regulator of T cell activity in the periphery. An
association of SHP-2 with CTLA-4 in mature peripheral T
cells has been demonstrated previously (32), and here we
demonstrate this association in thymocytes. The association of
SHP-2 with CTLA-4 was suggested to mediate a negative
signal imparted by CTLA-4. However, previous data have
implicated SHP-2 in a positive signaling role (33, 34), and the
inhibition of CD3–mediated depletion of DP thymocytes by
blockade of CTLA-4 observed here may indicate that
CTLA-4 signaling in fact is potentiating the signaling through
the TCR–CD3 receptor complex. The view of CTLA-4 as a
negative regulator has been recently challenged by others,
who suggest that CTLA-4 could act as a receptor mediating
costimulatory signals along with the signals mediated by the
TCR–CD3 receptor complex and the CD28 receptor (35).
The suggested function of CTLA-4 in thymic develop-
ment is in agreement with the initial reports of the Ctla-42/2
mice demonstrating an impairment in thymocyte develop-
ment (24, 25). However, they are in apparent contrast to
more recently presented analyses of these mice reporting no
major alterations in cell numbers, kinetics of development, or
distribution of subpopulations (27, 28). These recent papers
indicate that the CTLA-4 is primarily involved in the regula-
tion of peripheral T cell activation. Reinterpreted within the
frame of a suggested positive signaling through CTLA-4,
these data may still be compatible with a functional role of
CTLA-4 in the thymus. Current views hold that the signaling
of positive versus negative selection mediated by the TCR–
MHC complex is determined on the basis of the overall avid-
ity of this interaction (1). If, as suggested, CTLA-4 mediates a
positive costimulatory signal, the interaction of CTLA-4 with
its B7 ligands would produce an additive effect to the TCR-
MHC interaction during thymic selection, thus strengthening
the signals mediated through the TCR. The CD28 and the
CTLA-4 costimulatory receptors would, at least in this re-
spect, have similar modes of action.
Due to the difference in avidity for their ligands, differ-
ent kinetics of expression, and association with different
signaling molecules (6, 11, 15), CD28 and CTLA-4 may
still play fundamentally different roles in the thymic selec-
tion process. Thus, the higher avidity of CTLA-4 to B-7
and the fact that it is only expressed upon activation is
compatible with a mainly negative regulatory function,
Figure 5. Intrathymic CTLA-4
blockade inhibits anti-CD3–
mediated depletion of DP thy-
mocytes. Groups of three mice
were intrathymically injected with
soluble anti–CTLA-4, with only
saline or with anti-TNP hamster
Ig as controls before administra-
tion of anti-CD3. Thymocytes
were double stained with anti-
CD4–PE and anti-CD8–FITC
and analyzed by flow cytometry.
Dot-plots represent CD4/CD8
profiles of thymocytes from (A) mice injected with saline intraperitoneally
(i.p.) and intrathymically (i.t.), (B) mice injected with 100 mg anti-CD3 in-
traperitoneally and saline intrathymically, (C) mice injected with 100 mg
anti-CD3 intraperitoneally and hamster Ig intrathymically, (D) mice injected
with 100 mg anti-CD3 intraperitoneally and anti–CTLA-4 intrathymically.
Percentages of DP thymocytes are shown on the upper right quadrant of
each dot-plot. (E) Thymocytes recovered from mice (three mice each
group) treated with increasing amounts of anti-CD3 and injected intrathy-
mically either with anti-CTLA-4 or only saline were double stained with
anti-CD4 and anti-CD8 as above. These results are expressed as the mean
value 6 SD and are representative of at least three independent experiments.1244 A Role for CTLA-4 in the Thymus
mediated through the surpassing of a threshold of T cell
signaling leading to cell death rather than activation and
further differentiation. In this way, a defective CTLA-4 ex-
pression is likely to result in the skewing of TCR affinities
rather than in largely distorted cell numbers or alterations
in the various subpopulations that represent unique stages
of the differentiation process. Thus, the suggested function
of CTLA-4 during thymocyte differentiation may not be
incompatible with relatively normal cell numbers and sub-
set distribution in Ctla-42/2 mice (27, 28).
Our data suggest a model that predicts a skewing towards
increased mean affinities for self-MHC–peptide complexes
in mice with defective CTLA-4 function or expression. In
the Ctla-42/2 mice the predicted bias towards self-reactiv-
ity could, together with a defective peripheral control of T
cell activity, contribute to the massive lymphoproliferation
observed in these mice. This scenario also provides a plau-
sible mechanism for the contribution of CTLA-4 in mice
and humans with autoimmune disorders that have been ge-
netically linked to the Ctla-4 gene (36–41). The predicted
repertoire skewing in recent thymic emigrants in these
cases could be tested.
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